Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00064194
Other study ID # PRP1
Secondary ID CAN-NCIC-PRP1CDR
Status Completed
Phase Phase 3
First received
Last updated
Start date November 28, 2001
Est. completion date April 30, 2008

Study information

Verified date April 2020
Source Canadian Cancer Trials Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development or recurrence of cancer. Vitamin E, selenium, and soy protein may be effective in preventing the development of prostate cancer.

PURPOSE: Randomized phase III trial to study the effectiveness of combining vitamin E, selenium, and soy protein in preventing prostate cancer in patients who have high-grade prostate neoplasia.


Description:

OBJECTIVES:

- Determine whether nutritional supplementation with soy protein isolate, vitamin E, and selenium can delay the time to development of invasive prostate cancer (disease-free survival) in patients with high-grade prostatic intraepithelial neoplasia.

- Determine the effect of this supplementation on intermediate endpoints that may reflect a lessened risk of invasive prostate cancer (e.g., serum PSA levels, hormone levels, lycopene, malondialdehyde, vitamin E, and reduced thiol groups) in these patients.

- Determine the safety of this supplementation in these patients.

OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to participating center. Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive oral vitamin E, oral selenium, and oral soy protein isolate twice daily.

- Arm II: Patients receive oral placebo twice daily. In both arms, treatment continues for 3 years in the absence of invasive prostate cancer (demonstrated on biopsy) or unacceptable toxicity.

Patients are followed every 3 months for 1 year and then every 6 months for 2 years.

PROJECTED ACCRUAL: A total of 306 patients (153 per treatment arm) will be accrued for this study within 6 years.


Recruitment information / eligibility

Status Completed
Enrollment 310
Est. completion date April 30, 2008
Est. primary completion date April 30, 2008
Accepts healthy volunteers No
Gender Male
Age group N/A to 120 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed high-grade prostatic intraepithelial neoplasia (HGPIN)

- No evidence of invasive prostate cancer by at least 2 biopsies within the past 18 months

- At least 1 biopsy must show evidence of HGPIN within the past 6 months

- No prior invasive prostate cancer

PATIENT CHARACTERISTICS:

Age

- Not specified

Performance status

- Not specified

Life expectancy

- More than 5 years

Hematopoietic

- Platelet count at least 75,000/mm^3

- No coagulopathies

Hepatic

- Bilirubin no greater than 2 times upper limit of normal (ULN)

- PT (INR) no greater than 1.5 times ULN

- PTT no greater than 1.5 times ULN

- No hepatic insufficiencies

Renal

- Creatinine no greater than 2 times ULN

- No renal insufficiencies

Other

- No prior nonmelanoma skin cancer (e.g., squamous cell or basal cell carcinoma)

- No other malignancy within the past 5 years except superficial bladder cancer

- No known bowel malabsorption

- No dietary behavior (e.g., morbid obesity or eating disorders) that would limit adherence to study therapy

- No major illness, including psychiatric illness, that would preclude study compliance and follow-up

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- Not specified

Endocrine therapy

- More than 3 months since prior androgen therapy

- More than 3 months since prior hormonal therapy for benign prostatic hyperplasia (e.g., finasteride)

- No concurrent finasteride

- No concurrent androgen therapy

Radiotherapy

- More than 2 years since prior radiotherapy to the pelvic region

Surgery

- Not specified

Other

- More than 2 weeks since prior supplemental vitamin E or selenium

- No other concurrent vitamin E (greater than 100 IU/day), selenium, or soy protein isolate (more than 2 servings/week)

- No other concurrent treatment for high-grade prostatic intraepithelial neoplasia

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
selenium

soy protein isolate

vitamin E


Locations

Country Name City State
Canada Nova Scotia Cancer Centre Halifax Nova Scotia
Canada Princess Margaret Hospital Toronto Ontario
Canada Toronto Sunnybrook Regional Cancer Centre Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
NCIC Clinical Trials Group

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Fleshner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K, Farley A, Jansz K, Siemens DR, Trpkov K, Lacombe L, Gleave M, Tu D, Parulekar WR. Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination — View Citation

See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A